Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 622

1.

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.

Nakamura K, Smyth MJ.

Cell Mol Immunol. 2019 Oct 14. doi: 10.1038/s41423-019-0306-1. [Epub ahead of print] Review.

PMID:
31611651
2.

Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.

Dougall WC, Roman Aguilera A, Smyth MJ.

Clin Transl Immunology. 2019 Sep 27;8(10):e01081. doi: 10.1002/cti2.1081. eCollection 2019.

3.

Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23.

Kansara M, Thomson K, Pang P, Dutour A, Mirabello L, Acher F, Pin JP, Demicco EG, Yan J, Teng MWL, Smyth MJ, Thomas DM.

Cancer Discov. 2019 Sep 16. doi: 10.1158/2159-8290.CD-19-0154. [Epub ahead of print]

PMID:
31527131
4.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.

Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L.

Cell Res. 2019 Oct;29(10):846-861. doi: 10.1038/s41422-019-0224-x. Epub 2019 Sep 3.

PMID:
31481761
5.

Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.

Guillerey C, Nakamura K, Pichler AC, Barkauskas D, Krumeich S, Stannard K, Miles K, Harjunpää H, Yu Y, Casey M, Doban AI, Lazar M, Hartel G, Smith D, Vuckovic S, Teng MW, Bergsagel PL, Chesi M, Hill GR, Martinet L, Smyth MJ.

JCI Insight. 2019 Jun 13;5. pii: 125932. doi: 10.1172/jci.insight.125932.

6.

Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions.

Stannard KA, Lemoine S, Waterhouse NJ, Vari F, Chatenoud L, Gandhi MK, Martinet L, Smyth MJ, Guillerey C.

Blood Adv. 2019 Jun 11;3(11):1681-1694. doi: 10.1182/bloodadvances.2018030676.

7.

The role of NK cells and CD39 in the immunological control of tumor metastases.

Zhang H, Vijayan D, Li XY, Robson SC, Geetha N, Teng MWL, Smyth MJ.

Oncoimmunology. 2019 Apr 2;8(6):e1593809. doi: 10.1080/2162402X.2019.1593809. eCollection 2019.

PMID:
31069159
8.

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome.

Liu J, O'Donnell JS, Yan J, Madore J, Allen S, Smyth MJ, Teng MWL.

Oncoimmunology. 2019 Mar 1;8(5):e1581530. doi: 10.1080/2162402X.2019.1581530. eCollection 2019.

PMID:
31069141
9.

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.

O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL.

Clin Cancer Res. 2019 Oct 1;25(19):5743-5751. doi: 10.1158/1078-0432.CCR-18-2641. Epub 2019 Apr 30. Review.

PMID:
31040150
10.

Hide and seek: Plasticity of innate lymphoid cells in cancer.

Bald T, Wagner M, Gao Y, Koyasu S, Smyth MJ.

Semin Immunol. 2019 Feb;41:101273. doi: 10.1016/j.smim.2019.04.001. Epub 2019 Apr 9. Review.

PMID:
30979591
11.

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.

Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, Scolyer RA, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ.

Cancer Immunol Res. 2019 Apr;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20.

12.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group.

Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.

PMID:
30765258
13.

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Liu J, Rozeman EA, O'Donnell JS, Allen S, Fanchi L, Smyth MJ, Blank CU, Teng MWL.

Oncoimmunology. 2018 Nov 22;8(2):e1546068. doi: 10.1080/2162402X.2018.1546068. eCollection 2019.

PMID:
30713806
14.

An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.

Liede A, Hernandez RK, Wade SW, Bo R, Nussbaum NC, Ahern E, Dougall WC, Smyth MJ.

Oncoimmunology. 2018 Sep 5;7(12):e1480301. doi: 10.1080/2162402X.2018.1480301. eCollection 2018.

15.

Cancer immunoediting and resistance to T cell-based immunotherapy.

O'Donnell JS, Teng MWL, Smyth MJ.

Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi: 10.1038/s41571-018-0142-8. Review.

PMID:
30523282
16.

2018 Nobel Prize in physiology or medicine.

Smyth MJ, Teng MW.

Clin Transl Immunology. 2018 Oct 24;7(10):e1041. doi: 10.1002/cti2.1041. eCollection 2018. No abstract available.

17.

Bone marrow transplantation generates T cell-dependent control of myeloma in mice.

Vuckovic S, Minnie SA, Smith D, Gartlan KH, Watkins TS, Markey KA, Mukhopadhyay P, Guillerey C, Kuns RD, Locke KR, Pritchard AL, Johansson PA, Varelias A, Zhang P, Huntington ND, Waddell N, Chesi M, Miles JJ, Smyth MJ, Hill GR.

J Clin Invest. 2019 Jan 2;129(1):106-121. doi: 10.1172/JCI98888. Epub 2018 Nov 19.

18.

Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy.

Ahern E, Smyth MJ, Dougall WC, Teng MWL.

Nat Rev Clin Oncol. 2018 Nov;15(11):676-693. doi: 10.1038/s41571-018-0095-y. Review.

PMID:
30232468
19.

The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells.

Lepletier A, Lutzky VP, Mittal D, Stannard K, Watkins TS, Ratnatunga CN, Smith C, McGuire HM, Kemp RA, Mukhopadhyay P, Waddell N, Smyth MJ, Dougall WC, Miles JJ.

Immunol Cell Biol. 2019 Feb;97(2):152-164. doi: 10.1111/imcb.12205. Epub 2018 Oct 17.

PMID:
30222899
20.

Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade.

Mittal D, Vijayan D, Smyth MJ.

Cancer Discov. 2018 Sep;8(9):1066-1068. doi: 10.1158/2159-8290.CD-18-0798.

21.

Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.

Minnie SA, Kuns RD, Gartlan KH, Zhang P, Wilkinson AN, Samson L, Guillerey C, Engwerda C, MacDonald KPA, Smyth MJ, Markey KA, Vuckovic S, Hill GR.

Blood. 2018 Oct 18;132(16):1675-1688. doi: 10.1182/blood-2018-01-825240. Epub 2018 Aug 28.

PMID:
30154111
22.

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.

Guillerey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K, Krumeich S, Weulersse M, Cuisinier M, Stannard K, Yu Y, Minnie SA, Hill GR, Dougall WC, Avet-Loiseau H, Teng MWL, Nakamura K, Martinet L, Smyth MJ.

Blood. 2018 Oct 18;132(16):1689-1694. doi: 10.1182/blood-2018-01-825265. Epub 2018 Jul 9.

PMID:
29986909
23.

Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23.

Yan J, Allen S, Vijayan D, Li XY, Harjunpää H, Takeda K, Liu J, Cua DJ, Smyth MJ, Teng MWL.

Cancer Immunol Res. 2018 Aug;6(8):978-987. doi: 10.1158/2326-6066.CIR-18-0011. Epub 2018 Jun 19.

24.

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Harjunpää H, Blake SJ, Ahern E, Allen S, Liu J, Yan J, Lutzky V, Takeda K, Aguilera AR, Guillerey C, Mittal D, Li XY, Dougall WC, Smyth MJ, Teng MWL.

Oncoimmunology. 2018 Mar 26;7(7):e1445949. doi: 10.1080/2162402X.2018.1445949. eCollection 2018.

25.

TGFβ shuts the door on T cells.

Bald T, Smyth MJ.

Br J Cancer. 2018 Jul;119(1):1-3. doi: 10.1038/s41416-018-0122-x. Epub 2018 Jun 14.

26.

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Ahern E, Harjunpää H, O'Donnell JS, Allen S, Dougall WC, Teng MWL, Smyth MJ.

Oncoimmunology. 2018 Feb 14;7(6):e1431088. doi: 10.1080/2162402X.2018.1431088. eCollection 2018.

27.

Aberrant erythropoiesis fuels tumor growth.

Nakamura K, Smyth MJ.

Cell Res. 2018 Jun;28(6):611-612. doi: 10.1038/s41422-018-0047-1. No abstract available.

28.

Remote physiological monitoring in an austere environment: a future for battlefield care provision?

Smyth MJ, Round JA, Mellor AJ.

J R Army Med Corps. 2018 Nov;164(6):410-413. doi: 10.1136/jramc-2017-000905. Epub 2018 May 14.

PMID:
29764915
29.

CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ.

J Clin Invest. 2018 Jun 1;128(6):2613-2625. doi: 10.1172/JCI98769. Epub 2018 May 14.

30.

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Roman Aguilera A, Lutzky VP, Mittal D, Li XY, Stannard K, Takeda K, Bernhardt G, Teng MWL, Dougall WC, Smyth MJ.

Oncoimmunology. 2018 Feb 1;7(5):e1424677. doi: 10.1080/2162402X.2018.1424677. eCollection 2018.

31.

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.

Nakamura K, Kassem S, Cleynen A, Chrétien ML, Guillerey C, Putz EM, Bald T, Förster I, Vuckovic S, Hill GR, Masters SL, Chesi M, Bergsagel PL, Avet-Loiseau H, Martinet L, Smyth MJ.

Cancer Cell. 2018 Apr 9;33(4):634-648.e5. doi: 10.1016/j.ccell.2018.02.007.

32.

Rapid loss of group 1 innate lymphoid cells during blood stage Plasmodium infection.

Ng SS, Souza-Fonseca-Guimaraes F, Rivera FL, Amante FH, Kumar R, Gao Y, Sheel M, Beattie L, Montes de Oca M, Guillerey C, Edwards CL, Faleiro RJ, Frame T, Bunn PT, Vivier E, Godfrey DI, Pellicci DG, Lopez JA, Andrews KT, Huntington ND, Smyth MJ, McCarthy J, Engwerda CR.

Clin Transl Immunology. 2018 Jan 12;7(1):e1003. doi: 10.1002/cti2.1003. eCollection 2018.

33.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.

Mastaglio S, Wong E, Perera T, Ripley J, Blombery P, Smyth MJ, Koldej R, Ritchie D.

Blood Adv. 2018 Feb 27;2(4):335-346. doi: 10.1182/bloodadvances.2017015230.

34.

Flt-3L Expansion of Recipient CD8α+ Dendritic Cells Deletes Alloreactive Donor T Cells and Represents an Alternative to Posttransplant Cyclophosphamide for the Prevention of GVHD.

Markey KA, Kuns RD, Browne DJ, Gartlan KH, Robb RJ, Martins JP, Henden AS, Minnie SA, Cheong M, Koyama M, Smyth MJ, Steptoe RJ, Belz GT, Brocker T, Degli-Esposti MA, Lane SW, Hill GR.

Clin Cancer Res. 2018 Apr 1;24(7):1604-1616. doi: 10.1158/1078-0432.CCR-17-2148. Epub 2018 Jan 24.

35.

Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT.

Gartlan KH, Varelias A, Koyama M, Robb RJ, Markey KA, Chang K, Wilkinson AN, Smith D, Ullah MA, Kuns RD, Raffelt NC, Olver SD, Lineburg KE, Teal BE, Cheong M, Teng MWL, Smyth MJ, Tey SK, MacDonald KPA, Hill GR.

Blood Adv. 2017 Jan 26;1(6):341-351. doi: 10.1182/bloodadvances.2016002980. eCollection 2017 Feb 14.

36.

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.

Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ.

Cancer Res. 2018 Feb 15;78(4):1003-1016. doi: 10.1158/0008-5472.CAN-17-2826. Epub 2017 Dec 11.

37.

Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.

Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, Demir IE, Armbrecht N, Ceyhan GO, Manns MP, Wirth TC, Kubicka S, Bernhardt G, Smyth MJ, Calvisi DF, Gürlevik E, Kühnel F.

Cancer Res. 2018 Jan 15;78(2):475-488. doi: 10.1158/0008-5472.CAN-17-2415. Epub 2017 Nov 27.

38.

Targeting immunosuppressive adenosine in cancer.

Vijayan D, Young A, Teng MWL, Smyth MJ.

Nat Rev Cancer. 2017 Nov 22;17(12):765. doi: 10.1038/nrc.2017.110. No abstract available.

PMID:
29162946
39.

Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis.

Mittal D, Vijayan D, Putz EM, Aguilera AR, Markey KA, Straube J, Kazakoff S, Nutt SL, Takeda K, Hill GR, Waddell N, Smyth MJ.

Cancer Immunol Res. 2017 Dec;5(12):1098-1108. doi: 10.1158/2326-6066.CIR-17-0341. Epub 2017 Oct 25.

40.

Targeting immunosuppressive adenosine in cancer.

Vijayan D, Young A, Teng MWL, Smyth MJ.

Nat Rev Cancer. 2017 Dec;17(12):709-724. doi: 10.1038/nrc.2017.86. Epub 2017 Oct 23. Review. Erratum in: Nat Rev Cancer. 2017 Nov 22;17 (12 ):765.

PMID:
29059149
41.

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M.

Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.

42.

Cytokine-driven role of Srebps in killer cell metabolism.

Guillerey C, Smyth MJ.

Nat Immunol. 2017 Oct 18;18(11):1183-1184. doi: 10.1038/ni.3855. No abstract available.

PMID:
29044236
43.

TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.

Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L.

Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018.

44.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

45.

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, José V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J.

Cancer Res. 2017 Oct 15;77(20):5652-5663. doi: 10.1158/0008-5472.CAN-17-0707. Epub 2017 Aug 30.

46.

Control of Metastasis by NK Cells.

López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L.

Cancer Cell. 2017 Aug 14;32(2):135-154. doi: 10.1016/j.ccell.2017.06.009. Review.

47.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ.

Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31.

PMID:
28759001
48.

Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Yan J, Smyth MJ, Teng MWL.

Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7). pii: a028530. doi: 10.1101/cshperspect.a028530. Review.

PMID:
28716888
49.

PD1 functions by inhibiting CD28-mediated co-stimulation.

O'Donnell JS, Smyth MJ, Teng MWL.

Clin Transl Immunology. 2017 May 5;6(5):e138. doi: 10.1038/cti.2017.15. eCollection 2017 May. No abstract available.

50.

Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.

Zhao Y, Ting KK, Li J, Cogger VC, Chen J, Johansson-Percival A, Ngiow SF, Holst J, Grau G, Goel S, Muller T, Dejana E, McCaughan G, Smyth MJ, Ganss R, Vadas MA, Gamble JR.

Cancer Res. 2017 Aug 15;77(16):4434-4447. doi: 10.1158/0008-5472.CAN-16-3129. Epub 2017 Jun 27. Erratum in: Cancer Res. 2018 Oct 1;78(19):5718.

Supplemental Content

Loading ...
Support Center